Please login to the form below

Not currently logged in
Email:
Password:

Sumitomo Dainippon

This page shows the latest Sumitomo Dainippon news and features for those working in and with pharma, biotech and healthcare.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer

The positive trial result is also good news for Japanese drugmaker  Sumitomo Dainippon, which agreed a $3bn upfront deal to acquire a 45% stake in Myovant – and control of four other

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • A snapshot of… Exscientia A snapshot of… Exscientia

    We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials.

  • The good, the bad and the ugly The good, the bad and the ugly

    2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo Dainippon Pharma (25%), with growth ... However, the imminent US patent expiry of Sumitomo

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML. ... Tolero Pharmaceuticals. Dainippon Sumitomo. $780m. Upfront payment of $200m.

  • Deal Watch August 2016 Deal Watch August 2016

    If apomorphine is the only product, the acquisition of the company by Sunovion (the US subsidiary of Dainippon Sumitomo) for $645m, paying a hefty 123% share price premium, looks very expensive ... 645. Cynapsys (CA). Sunovion (US) (Dainippon Sumitomo).

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Edison Pharmaceuticals/ Dainippon Sumitomo Pharma. Strategic alliance. Extends development/ commercialisation agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Civitas appoints Mark Iwicki as CEO Civitas appoints Mark Iwicki as CEO

    Sunovion was created after the acquisition of Iwicki's former company Sepracor by Dainippon Sumitomo Pharmaceuticals.

  • Boston Biomedical appoints commercial head Boston Biomedical appoints commercial head

    Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics